Shearluc that is a very helpful post |
After the last raise, the company is funded through to July / August by which time a deal is very likely to be signed.
There is a lot going on behind the scenes, which we should be hearing about soon! |
This stock appears to be a pump and dump.
Each time they need to raise money the mm pump.
How long have they got B before the next raise |
The royalties (if we ever get to see any) are not 2 million. They are capped at 2 million. We don't even know how much revenue Oxilio would have to generate in or to pay 2 million |
They haven't received any royalties |
Are nuformix still receiving royalties from oxillio of around 2 million pounds annually |
Bid seems to be slipping again |
The application for NXP002 follows a positive pre-submission meeting with the EMA, where the company was advised to proceed.Nuformix also confirmed ongoing discussions with potential partners to secure a licensing or option agreement for NXP002. |
Dr Julian Gilbert, Non-Executive Chairman, has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at a number of companies including Chiroscience Plc, Mundipharma International Limited, British Technology Group plc (BTG) and Smith Kline & French (now GlaxoSmithKline plc).The Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center will collaborate with GSK to develop stem cell-based models to better understand pulmonary fibrosis and identify new targets for treatments that may halt or slow its progression."This exciting collaboration with GSK will help ... make meaningful progress in the treatment of chronic lung diseases like pulmonary fibrosis," Darrell Kotton, MD, CReM's founding director and a professor of medicine at Boston University, said in a university news story. |
No news after 20th March agm I guess |
The collaboration between the ended years ago |
 RNS Number : 9259YNuformix PLC28 February 2025 28 February 2025 Nuformix plc ("Nuformix" or the "Company") Total Voting Rights Following the issue of new ordinary shares of 0.05p each in the Company ("Ordinary Shares"), as announced on 30 January 2025, the Company is today providing a confirmation regarding its voting rights, in line with section DTR 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules sourcebook. As of the date of this announcement, the Company's issued ordinary share capital consists of 1,669,309,368 Ordinary Shares, each with one voting right. The Company does not hold any Ordinary Shares in treasury. The total voting rights figure is therefore 1,669,309,368 and this can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority. Enquiries: Nuformix plc Dr Dan Gooding, Executive Director Via IFC Advisory CMC MarketsDouglas Crippen+44 (0) 20 3003 8632IFC Advisory LimitedTim MetcalfeZach Cohen+44 (0) 20 3934 6630nuformix@investor-focus.co.uk About Nuformix Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities. For more information, please visit www.nuformix.com. |
The Vistagen post is 5 years old |
Might see some development here |
https://www.vistagen.com/news-releases/news-release-details/vistagen-and-nuformix-announce-agreement-develop-novel |
https://www.businesswire.com/news/home/20250205861934/en/Vistagen-Receives-U.S.-Patent-for-AV-101-to-Treat-Neuropathic-Pain |
Press ReleaseVistagen Receives U.S. Patent for AV-101 to Treat Neuropathic PainFebruary 5, 2025 |
Need an rns out |
TRLS, similar position but not in pharmaceutical |
If it happens to be a partner |
Sorry NxP004Not nxp002 |
AstraZeneca's Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalDataImagine NXP002, in the market |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
